Next Article in Journal
Exploring Definitions of “Addiction” in Adolescents and Young Adults and Correlation with Substance Use Behaviors
Previous Article in Journal
Getting to the Bottom of Saddle Sores: A Scoping Review of the Definition, Prevalence, Management and Prevention of Saddle Sores in Cycling
Previous Article in Special Issue
Maternal Food and Beverage Consumption Behaviors and Discrepant Phthalate Exposure by Race
 
 
Article
Peer-Review Record

Does Older Age Modify Associations between Endocrine Disrupting Chemicals and Fecundability?

Int. J. Environ. Res. Public Health 2022, 19(13), 8074; https://doi.org/10.3390/ijerph19138074
by Anna Z. Pollack 1,*, Jenna R. Krall 1, Shanna H. Swan 2 and Germaine M. Buck Louis 1
Reviewer 1:
Reviewer 2: Anonymous
Int. J. Environ. Res. Public Health 2022, 19(13), 8074; https://doi.org/10.3390/ijerph19138074
Submission received: 3 May 2022 / Revised: 16 June 2022 / Accepted: 27 June 2022 / Published: 30 June 2022

Round 1

Reviewer 1 Report


Comments for author File: Comments.pdf

Author Response

Please see the attachment

Author Response File: Author Response.docx

Reviewer 2 Report

The purpose and hypothesis need to be stated in the introduction.

Why limit the recruitment age of the females but not the males. The fertility of males decreases with older age, which directly influences pregnancy outcomes. 

Table 1 and figure 1 legend needs abbreviations. 

 

Author Response

Please see attachment 

Author Response File: Author Response.docx

Reviewer 3 Report

The manuscript titled "Does older age modify associations between endocrine disrupting chemicals and fecundability?" is a very interesting paper in the field of endocrine disrupters. The overall structure is of good quality, introduction and methods are clear and results are of good quality. References are of good quality and cover the principal areas of the research. However, authors should improve the mansucriot in several parts:

1) in the introduction, authors should improve the description of possible increased risk od cardiovascular events in patients vulnerable like cancer patients ( you can cite doi: 10.1016/j.etap.2019.03.006. )

2) authors should explain how some nutraceuticals like curcumin should reduce the side effects of BPA through PPAR and pAMPK pathways.

3) authors should explain how nanoformulation of antioxidants should reduces the side effects of BPA and other endocrine disrupters in preclinical and clinical models ( i.e also in cancer bearing mice). cite 10.1016/j.nano.2016.08.022

Author Response

Please see the attachment 

Author Response File: Author Response.docx

Back to TopTop